Schrodinger (NASDAQ:SDGR) EVP Yvonne Tran Sells 32,000 Shares of Company Stock

Schrodinger, Inc. (NASDAQ:SDGR) EVP Yvonne Tran sold 32,000 shares of the business’s stock in a transaction on Monday, November 9th. The stock was sold at an average price of $32.85, for a total transaction of $1,051,200.00. Following the sale, the executive vice president owned 52,683 shares in the company, valued at $1,730,636.55. The trade was a 37.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Schrodinger Stock Down 2.9%

NASDAQ:SDGR opened at $32.41 on Wednesday. The firm’s fifty day simple moving average is $26.33 and its 200-day simple moving average is $17.24. The stock has a market cap of $2.39 billion, a PE ratio of -41.02 and a beta of 1.69. Schrodinger, Inc. has a fifty-two week low of $10.94 and a fifty-two week high of $33.78.

Schrodinger (NASDAQ:SDGR) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.17. Schrodinger had a negative net margin of 22.02% and a negative return on equity of 18.12%. The firm had revenue of $64.49 million during the quarter, compared to analysts’ expectations of $47.73 million. During the same quarter last year, the business earned ($0.45) earnings per share. The business’s revenue for the quarter was up 18.7% compared to the same quarter last year. Equities analysts anticipate that Schrodinger, Inc. will post -1.39 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on SDGR. TD Cowen lifted their price target on shares of Schrodinger from $31.00 to $36.00 and gave the company a “buy” rating in a research report on Thursday, November 5th. Zacks Research lowered Schrodinger from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 3rd. BMO Capital Markets upped their price target on Schrodinger from $24.00 to $30.00 and gave the stock an “outperform” rating in a report on Monday, October 12th. UBS Group upped their price target on Schrodinger from $19.00 to $21.00 and gave the stock a “neutral” rating in a report on Tuesday, October 20th. Finally, Wall Street Zen raised Schrodinger from a “strong sell” rating to a “hold” rating in a research note on Saturday, August 8th. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $26.67.

Institutional Investors Weigh In On Schrodinger

Several institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. acquired a new stake in Schrodinger in the 2nd quarter valued at about $170,978,000. Rubric Capital Management LP raised its position in Schrodinger by 43.8% during the first quarter. Rubric Capital Management LP now owns 6,000,000 shares of the company’s stock worth $68,160,000 after acquiring an additional 1,828,502 shares during the last quarter. Amova Asset Management Americas Inc. lifted its holdings in shares of Schrodinger by 13.2% in the first quarter. Amova Asset Management Americas Inc. now owns 3,190,837 shares of the company’s stock valued at $36,248,000 after purchasing an additional 371,167 shares in the last quarter. Public Sector Pension Investment Board lifted its holdings in shares of Schrodinger by 79.0% in the third quarter. Public Sector Pension Investment Board now owns 350,738 shares of the company’s stock valued at $10,890,000 after purchasing an additional 154,824 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Schrodinger in the second quarter valued at about $4,986,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

About Schrodinger

Schrödinger, Inc. develops computational software used to support drug discovery and materials research. Its platform applies physics-based modeling, computational chemistry and machine learning to help researchers analyze molecular properties and identify promising candidates. The company’s tools are used by pharmaceutical and biotechnology companies, academic institutions and other research organizations. Alongside software sales and subscriptions, Schrödinger works with partners on drug discovery programs and advances a portfolio of its own therapeutic candidates.